Advertisement
Screener

EXAGEN INC. (XGN) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum

2.3 / 5 stars · 32/70 Roast Me

EXAGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum

EXAGEN INC. (XGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 0.10% for the 9-month period ending 2020-09-30, per its 10-Q filed 2021-11-10.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2021-11-10

  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2020-03-31 was 0.60%.
  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2019 was 1.60%, a 14.29% increase from fiscal 2018.
  • EXAGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2018 was 1.40%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month
2020-09-300.10%
10-Q · filed 2021-11-10
0.40%
10-Q · filed 2020-11-10
2020-06-300.40%
10-Q · filed 2020-07-28
2020-03-310.60%
10-Q · filed 2020-05-11
2019-12-311.60%
10-K · filed 2020-03-25
2019-09-302.00%
10-Q · filed 2020-11-10
2018-12-311.40%
10-K · filed 2020-03-25
2018-09-301.40%
10-Q · filed 2019-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Freenome, Inc. (FRNM)United States$0.143B
BIODESIX INC (BDSX)United States$0.312B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45